ERBB2 and non-small cell lung carcinoma: Of the classic non-small-cell lung cancer oncogenic driver mutations, only two were detected in two patients, a KRAS G12D in a stage IIIA patient (P27, Fig. 1) and an ERBB2 gene amplification in a stage IVA patient (P06, Fig. 1).